Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

Chair and Professor of Medicinal Chemistry, Joseph P. & Shirley Shipman Buckley Endowed Professor of Drug Discovery Synthetic medicinal chemistry, structure-based design, natural product chemistry ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove safe and effective for chronic pain.

Applicants to the Ph.D. program Concentrations in Medicinal Chemistry, Pharmaceutics and Pharmacology must have, or nearly have, at least a Bachelor’s degree in pharmacy, biology, biochemistry, ...

Vertex Pharmaceuticals' suzetrigine showed lackluster Phase II results, but I still see potential in the non-addictive pain management market given the opioid crisis. Vertex's dominance in the ...

Houston-based Vertex Energy Inc. (OTCPK: VTNRQ) has released its restructuring plan after filing for bankruptcy protection with a move that will cancel and restructure all of its current stock.

NEW YORK, NY / ACCESS Newswire / January 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...